In the ONYX-015 highly sensitive, p53 functional IGRG121, concomitant therapy at the same dose of irradiation and ONYX-015 at a 10 times lower virus dose, which, in itself was ‘subtherapeutic’, resulted in potentiated tumour growth delays and tumour-free survivors. This evidence concerns the gene TP53 and neoplasm.